Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Collegium Pharmaceutical

Canopy Growth (CGC) vs. Collegium Pharmaceutical (COLL): Which Pharma Stock Is the Better Buy for Growth Investors?

The pharma industry is poised for long-term growth supported by increasing demand for drugs worldwide and technological advancements. While leading pharma stocks Collegium Pharmaceutical (COLL) and Canopy Growth (CGC) should benefit from the industry tailwinds, let us determine which is the better buy.

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

Recap: Collegium Pharmaceutical Q1 Earnings

Recap: Collegium Pharmaceutical Q1 Earnings

Collegium Pharmaceutical (NASDAQ:COLL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

A Preview Of Collegium Pharmaceutical's Earnings

Collegium Pharmaceutical (NASDAQ:COLL) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Collegium Pharmaceutical will report an earnings per share (EPS) of $0.90.

5 Value Stocks To Watch In The Healthcare Sector

What Defines a Value Stock?

5 Value Stocks To Watch In The Healthcare Sector

What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Analyst Ratings For Collegium Pharmaceutical

Over the past 3 months, 4 analysts have published their opinion on Collegium Pharmaceutical (NASDAQ:COLL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

inkl

Read news from The Economist, FT, and more,
with one subscription

1

People

Steve Reitmeister

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Western Digital

Canaccord Genuity

Quest Diagnostics

Rhythm Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

384,460 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play